CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 30.79×, higher than 95% of its Biotechnology peers (median 5.5×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.99BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
416.16%vs all stocks
Market Capitalization
2.99BUSDvs all stocks (USD)
Enterprise Value
2.56BUSDvs all stocks (USD)
Forward P/E
-16.02xvs Biotechnology peers
Price to Book (MRQ)
6.84xvs Biotechnology peers
Enterprise to EBITDA
-25.93xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-17.68%vs Biotechnology peers
Return on Equity (TTM)
-25.73%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-98.56MUSDvs all stocks (USD)
Net Income (TTM)
-86.61MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-77.48MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-52.45MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-98.06MUSDvs all stocks (USD)
Pre-tax Income
-86.97MUSDFY2025 · Dec 31, 2025Net Income
-86.97MUSDFY2025 · Dec 31, 2025EBIT
-98.06MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-97.81MUSDFY2025 · Dec 31, 2025Research & Development
79.16MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
18.90MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
11.08MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-86.97MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-80.44MUSDFY2025 · Dec 31, 2025Free Cash Flow
-82.37MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
75.29MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-86.97MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
248.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
8.68MUSDFY2025 · Dec 31, 2025Other Non-cash Items
133.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-2.46MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-68.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.93MUSDFY2025 · Dec 31, 2025Purchase of Investments
-358.15MUSDFY2025 · Dec 31, 2025Sale of Investments
276.37MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-83.70MUSDFY2025 · Dec 31, 2025Other Financing Charges
-771.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
187.18MUSDFY2025 · Dec 31, 2025Shares Outstanding
47.57MSharesUpdated Jul 19, 2026Float Shares
27.05MSharesUpdated Jul 19, 2026Shares Short
5.90MSharesUpdated Jul 19, 2026Short Ratio
5.62daysvs all stocks
Short % of Shares Outstanding
17.38%vs all stocks
% Held by Insiders
2.70%vs all stocks
% Held by Institutions
120.25%vs all stocks
Total Cash (MRQ)
439.98MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
9.24USDUpdated Jul 19, 2026Total Debt (MRQ)
555.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0013xvs Biotechnology peers
Current Ratio (MRQ)
30.79xvs Biotechnology peers
Book Value per Share (MRQ)
9.20USDUpdated Jul 19, 2026Total Assets
385.14MUSDvs all stocks (USD)
Total Current Assets
381.54MUSDFY2025 · Dec 31, 2025Total Liabilities
15.92MUSDFY2025 · Dec 31, 2025Total Non-current Assets
3.60MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
426.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
15.49MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
75.29MUSDFY2025 · Dec 31, 2025Other Short-term Investments
298.42MUSDFY2025 · Dec 31, 2025Accounts Payable
2.98MUSDFY2025 · Dec 31, 2025Short-term Debt
172.00KUSDFY2025 · Dec 31, 2025Long-term Debt
424.00KUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
2.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
6.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-224.48MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
369.22MUSDvs all stocks (USD)
52-Week Low
9.63USDUpdated Jul 19, 202652-Week High
66.55USDUpdated Jul 19, 202652-Week Change
416.16%vs all stocks
50-Day MA
42.47USDUpdated Jul 19, 2026200-Day MA
32.65USDUpdated Jul 19, 2026Avg 10-Day Volume
925.45KSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.06MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-2.34USDUpdated Jul 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 30.79×, higher than 95% of its Biotechnology peers (median 5.5×)Significant
Current ratio: 30.79Industry median: 5.50Industry P95: 22.03Peers compared: 197
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.72
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $2.99B, above the global median of $1.15BNotable
Market cap (USD): 2,994,836,965Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Walvax Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Rubicon Research Limited
Tier 1ProductionApproval-Gated PipelineRule
Autobio Diagnostics Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Piramal Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yili Chuanning Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Chengdu Kanghong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Disc Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Haoyuan Chemexpress Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
BioArctic AB
Tier 1ProductionApproval-Gated PipelineRuleRisk
Ultragenyx Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Divgi Torqtransfer Systems Limited
1 interpretationLow-Leverage Liquidity Configuration
Uniparts India Ltd.
1 interpretationLow-Leverage Liquidity Configuration
Rapport Therapeutics Inc.
1 interpretationLow-Leverage Liquidity Configuration